NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹365 Cr | ₹262 Cr | ₹216 Cr | ₹194 Cr | ₹98 Cr |
What is the latest Total Current Liabilities ratio of NATH BIOGENES (INDIA) ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹365 Cr |
| Mar2024 | ₹262 Cr |
| Mar2023 | ₹216 Cr |
| Mar2022 | ₹194 Cr |
| Mar2013 | ₹98 Cr |
How is Total Current Liabilities of NATH BIOGENES (INDIA) Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹365 Cr | 39.19 | |
| Mar2024 | ₹262 Cr | 21.26 | |
| Mar2023 | ₹216 Cr | 11.40 | |
| Mar2022 | ₹194 Cr | 98.02 | |
| Mar2013 | ₹98 Cr | - | |
Compare Total Current Liabilities of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹312.9 Cr | -4.3% | -6.7% | -13.1% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹13,082.2 Cr | -1.4% | -0.9% | -31.9% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹5,496.3 Cr | 6.2% | 0.6% | 7.7% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,901.0 Cr | -3.1% | -8.9% | -23.1% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,230.4 Cr | -1.7% | -5.4% | -28.1% | Stock Analytics | |
| INDO US BIOTECH | ₹260.9 Cr | -2.5% | -0.5% | -46.4% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | -4.3% |
-6.7% |
-13.1% |
| SENSEX | 1.4% |
2.4% |
5.1% |
You may also like the below Video Courses